RET and medullary thyroid gland carcinoma: Although the initial clinical line of sight for this target was MTC, recent identification of RET fusions (e.g. KIF5B-RET and CCDC6-RET) present in approximately 1% of LAD patient samples offer an important disease segment in which a specific RET inhibitor would also offer clinical benefit.